205 related articles for article (PubMed ID: 16120550)
1. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
Comandone A; Passera R; Boglione A; Tagini V; Ferrari S; Cattel L
Acta Oncol; 2005; 44(4):406-11. PubMed ID: 16120550
[TBL] [Abstract][Full Text] [Related]
2. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
3. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate pharmacokinetics and survival in osteosarcoma.
Aquerreta I; Aldaz A; Giráldez J; Sierrasesúmaga L
Pediatr Blood Cancer; 2004 Jan; 42(1):52-8. PubMed ID: 14752795
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
8. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
10. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
12. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
13. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
[TBL] [Abstract][Full Text] [Related]
14. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
15. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
16. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.
Fujita Y; Nakamura T; Aomori T; Nishiba H; Shinozaki H; Yanagawa T; Takagishi K; Watanabe H; Okada Y; Nakamura K; Horiuchi R; Yamamoto K
J Chemother; 2010 Jun; 22(3):186-90. PubMed ID: 20566424
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
[TBL] [Abstract][Full Text] [Related]
20. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]